Utilization frequency and patient-reported effectiveness of symptomatic therapies in post-COVID syndrome.
COVID-19
Effectiveness
Medication
Post-COVID-19
Treatment
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
23 Sep 2024
23 Sep 2024
Historique:
received:
26
03
2024
accepted:
30
08
2024
medline:
24
9
2024
pubmed:
24
9
2024
entrez:
24
9
2024
Statut:
epublish
Résumé
To date there is no causal treatment for post-COVID syndrome, leaving symptomatic treatments as the primary recourse. However, the practical implementation and effectiveness of these interventions remain underexplored. This study aimed to investigate the utilization frequency of symptomatic therapies and patient-reported effectiveness across various treatment modalities at a German post-COVID center. As the baseline investigation we conducted a single-cohort retrospective study to analyze the frequency of symptomatic therapies among post-COVID patients who attended the post-COVID center of the University Hospital of Erlangen, between December 2022 to July 2023. Additionally, we administered a follow-up at least 3 months after the initial presentation, using a questionnaire to assess patient-reported improvements in post-COVID symptoms associated with the symptomatic therapies received. Our study included 200 patients (mean age: 44.6 ± 12.6 years; 69.0% women; mean duration since acute infection: 15.3 ± 8.3 months). Pharmacotherapy was the predominant symptomatic treatment (79.5%), with psychotropic drugs (32.5%) and analgesics (31.5%) being the most frequently prescribed. Over half of the patients (55.5%) utilized vitamins and nutritional supplements. Hospital admission rates to acute care occurred in 35.5% of cases; 33.0% underwent inpatient rehabilitation and 31.0% pursued outpatient psychotherapy. Cardiologists (76.5%), pulmonologists (67.5%), and neurologists (65.5%) were the most consulted specialists. Therapies involving medical devices were infrequently employed (12.0%). In a follow-up questionnaire (response rate: 82.5%, 6.3 ± 2.2 months post-baseline), beta-blockers were the most effective pharmacological intervention with 31.5% of patients reporting strong to very strong symptom improvement, followed by antibiotics (29.6%). Furthermore, 33.0% of the patients perceived plasmapheresis to strongly alleviate symptoms. Only a small proportion of the sample attributed a strong or very strong symptom improvement to outpatient psychotherapy (11.0%). This study provides initial insights into symptomatic therapy utilization and patient-reported symptom improvement in post-COVID syndrome. Further research into symptoms clusters and interdisciplinary collaboration are warranted to comprehensively address the multifaceted physical and psychological symptomatology. The study was registered at the German Clinical Trials Register (DRKS-ID: DRKS00033621) on March 20, 2024.
Sections du résumé
BACKGROUND
BACKGROUND
To date there is no causal treatment for post-COVID syndrome, leaving symptomatic treatments as the primary recourse. However, the practical implementation and effectiveness of these interventions remain underexplored. This study aimed to investigate the utilization frequency of symptomatic therapies and patient-reported effectiveness across various treatment modalities at a German post-COVID center.
METHODS
METHODS
As the baseline investigation we conducted a single-cohort retrospective study to analyze the frequency of symptomatic therapies among post-COVID patients who attended the post-COVID center of the University Hospital of Erlangen, between December 2022 to July 2023. Additionally, we administered a follow-up at least 3 months after the initial presentation, using a questionnaire to assess patient-reported improvements in post-COVID symptoms associated with the symptomatic therapies received.
RESULTS
RESULTS
Our study included 200 patients (mean age: 44.6 ± 12.6 years; 69.0% women; mean duration since acute infection: 15.3 ± 8.3 months). Pharmacotherapy was the predominant symptomatic treatment (79.5%), with psychotropic drugs (32.5%) and analgesics (31.5%) being the most frequently prescribed. Over half of the patients (55.5%) utilized vitamins and nutritional supplements. Hospital admission rates to acute care occurred in 35.5% of cases; 33.0% underwent inpatient rehabilitation and 31.0% pursued outpatient psychotherapy. Cardiologists (76.5%), pulmonologists (67.5%), and neurologists (65.5%) were the most consulted specialists. Therapies involving medical devices were infrequently employed (12.0%). In a follow-up questionnaire (response rate: 82.5%, 6.3 ± 2.2 months post-baseline), beta-blockers were the most effective pharmacological intervention with 31.5% of patients reporting strong to very strong symptom improvement, followed by antibiotics (29.6%). Furthermore, 33.0% of the patients perceived plasmapheresis to strongly alleviate symptoms. Only a small proportion of the sample attributed a strong or very strong symptom improvement to outpatient psychotherapy (11.0%).
CONCLUSION
CONCLUSIONS
This study provides initial insights into symptomatic therapy utilization and patient-reported symptom improvement in post-COVID syndrome. Further research into symptoms clusters and interdisciplinary collaboration are warranted to comprehensively address the multifaceted physical and psychological symptomatology.
TRIAL REGISTRATION
BACKGROUND
The study was registered at the German Clinical Trials Register (DRKS-ID: DRKS00033621) on March 20, 2024.
Identifiants
pubmed: 39313792
doi: 10.1186/s12889-024-19951-3
pii: 10.1186/s12889-024-19951-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2577Informations de copyright
© 2024. The Author(s).
Références
World Health Organization. Number of COVID-19 cases reported to WHO (cumulative total) 2024. https://data.who.int/dashboards/covid19/cases?n=c . Accessed 21. March 2024.
Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13(1):3528.
pubmed: 35764621
pmcid: 9240035
doi: 10.1038/s41467-022-30836-0
Kryuchkov I. Post COVID-19 condition (Long COVID): World Health Organization; 2022. https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition . Accessed 21. March 2024.
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–46.
pubmed: 36639608
pmcid: 9839201
doi: 10.1038/s41579-022-00846-2
Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23(2):194–202.
pubmed: 35105985
pmcid: 9127978
doi: 10.1038/s41590-021-01104-y
Hallek M, Adorjan K, Behrends U, Ertl G, Suttorp N, Lehmann C. Post-COVID syndrome. Dtsch Arztebl Int. 2023;120(4):48–55.
pubmed: 36633452
pmcid: 10060997
Najafi MB, Javanmard SH. Post-COVID-19 syndrome mechanisms, prevention and management. Int J Prev Med. 2023;14:59.
pubmed: 37351054
pmcid: 10284243
doi: 10.4103/ijpvm.ijpvm_508_21
Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021;53(10):737–54.
pubmed: 34024217
doi: 10.1080/23744235.2021.1924397
Haffke M, Freitag H, Rudolf G, Seifert M, Doehner W, Scherbakov N, et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). J Transl Med. 2022;20(1):138.
pubmed: 35317812
pmcid: 8938726
doi: 10.1186/s12967-022-03346-2
Charfeddine S, Ibn Hadj Amor H, Jdidi J, Torjmen S, Kraiem S, Hammami R, et al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front Cardiovasc Med. 2021;8:745758.
pubmed: 34917659
pmcid: 8670225
doi: 10.3389/fcvm.2021.745758
Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, de Maertens C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54(1):1473–87.
pubmed: 35594336
pmcid: 9132392
doi: 10.1080/07853890.2022.2076901
Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210–6.
pubmed: 35027728
doi: 10.1038/s41590-021-01113-x
Wallukat G, Hohberger B, Wenzel K, Fürst J, Schulze-Rothe S, Wallukat A, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100.
pubmed: 33880442
pmcid: 8049853
doi: 10.1016/j.jtauto.2021.100100
Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.
pubmed: 32784198
doi: 10.1136/bmj.m3026
Scheibenbogen C, Bellmann-Strobl JT, Heindrich C, Wittke K, Stein E, Franke C, et al. Fighting Post-COVID and ME/CFS - development of curative therapies. Front Med (Lausanne). 2023;10:1194754.
pubmed: 37396922
doi: 10.3389/fmed.2023.1194754
Harandi AA, Pakdaman H, Medghalchi A, Kimia N, Kazemian A, Siavoshi F, et al. A randomized open-label clinical trial on the effect of amantadine on post covid 19 fatigue. Sci Rep. 2024;14(1):1343.
pubmed: 38228731
pmcid: 10792128
doi: 10.1038/s41598-024-51904-z
Rus CP, de Vries BEK, de Vries IEJ, Nutma I, Kooij JJS. Treatment of 95 post-covid patients with SSRIs. Sci Rep. 2023;13(1):18599.
pubmed: 37919310
pmcid: 10622561
doi: 10.1038/s41598-023-45072-9
O’Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health. 2022;24:100485.
pubmed: 35814187
pmcid: 9250701
doi: 10.1016/j.bbih.2022.100485
Abdelnabi M, Saleh Y, Ahmed A, Benjanuwattra J, Leelaviwat N, Almaghraby A. Ivabradine effects on COVID-19-associated postural orthostatic tachycardia syndrome: a single center prospective study. Am J Cardiovasc Dis. 2023;13(3):162–7.
pubmed: 37469536
pmcid: 10352820
Raoof A. Comparison of the effiacy of β blocker and ivabradine in Post COVID-19 associated inappropriate sinus tachycardia. J Cardiovasc Disease Res. 2022;13(04,2022):57–63.
di Filippo L, Frara S, Nannipieri F, Cotellessa A, Locatelli M, Rovere Querini P, Giustina A. Low vitamin D levels are Associated with Long COVID Syndrome in COVID-19 survivors. J Clin Endocrinol Metab. 2023;108(10):e1106–16.
pubmed: 37051747
pmcid: 10505553
doi: 10.1210/clinem/dgad207
Rathi A, Jadhav SB, Shah N. A randomized controlled trial of the efficacy of systemic enzymes and probiotics in the resolution of Post-COVID fatigue. Med (Basel). 2021;8(9).
Liu TH, Ho CH, Chen DT, Wu JY, Huang PY, Lai CC, et al. Omega-3 polyunsaturated fatty acids and the psychiatric post-acute sequelae of COVID-19: a one-year retrospective cohort analysis of 33,908 patients. Brain Behav Immun. 2023;114:453–61.
pubmed: 37716377
doi: 10.1016/j.bbi.2023.09.008
Yang CP, Chang CM, Yang CC, Pariante CM, Su KP. Long COVID and long chain fatty acids (LCFAs): psychoneuroimmunity implication of omega-3 LCFAs in delayed consequences of COVID-19. Brain Behav Immun. 2022;103:19–27.
pubmed: 35390469
pmcid: 8977215
doi: 10.1016/j.bbi.2022.04.001
Vollbracht C, Kraft K. Feasibility of vitamin C in the treatment of post viral fatigue with focus on long COVID, based on a systematic review of IV vitamin C on fatigue. Nutrients. 2021;13(4).
Izzo R, Trimarco V, Mone P, Aloè T, Capra Marzani M, Diana A, et al. Combining L-Arginine with vitamin C improves long-COVID symptoms: the LINCOLN Survey. Pharmacol Res. 2022;183:106360.
pubmed: 35868478
pmcid: 9295384
doi: 10.1016/j.phrs.2022.106360
Hansen KS, Mogensen TH, Agergaard J, Schiøttz-Christensen B, Østergaard L, Vibholm LK, Leth S. High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: a randomized, phase 2, crossover trial. Lancet Reg Health Eur. 2023;24:100539.
pubmed: 36337437
doi: 10.1016/j.lanepe.2022.100539
Cabral-Marques O, Halpert G, Schimke LF, Ostrinski Y, Vojdani A, Baiocchi GC, et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat Commun. 2022;13(1):1220.
pubmed: 35264564
pmcid: 8907309
doi: 10.1038/s41467-022-28905-5
Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515).
Fox T, Hunt BJ, Ariens RA, Towers GJ, Lever R, Garner P, Kuehn R. Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition. Cochrane Database Syst Rev. 2023;7(7):Cd015775.
pubmed: 37491597
Lindenmann J, Porubsky C, Okresa L, Klemen H, Mykoliuk I, Roj A et al. Immediate and Long-Term effects of hyperbaric oxygenation in patients with long COVID-19 syndrome using SF-36 Survey and VAS score: a clinical pilot study. J Clin Med. 2023;12(19).
Pan JQ, Tian ZM, Xue LB. Hyperbaric oxygen treatment for long COVID: from molecular mechanism to clinical practice. Curr Med Sci. 2023;43(6):1061–5.
pubmed: 37924387
doi: 10.1007/s11596-023-2799-1
Huth D, Bräscher AK, Tholl S, Fiess J, Birke G, Herrmann C, et al. Cognitive-behavioral therapy for patients with post-COVID-19 condition (CBT-PCC): a feasibility trial. Psychol Med. 2024;54(6):1122–32.
pubmed: 37842765
doi: 10.1017/S0033291723002921
Kuut TA, Müller F, Csorba I, Braamse A, Aldenkamp A, Appelman B, et al. Efficacy of cognitive-behavioral therapy targeting severe fatigue following Coronavirus Disease 2019: results of a Randomized Controlled Trial. Clin Infect Dis. 2023;77(5):687–95.
pubmed: 37155736
pmcid: 10495128
doi: 10.1093/cid/ciad257
Fawzy NA, Abou Shaar B, Taha RM, Arabi TZ, Sabbah BN, Alkodaymi MS, et al. A systematic review of trials currently investigating therapeutic modalities for post-acute COVID-19 syndrome and registered on WHO International clinical trials platform. Clin Microbiol Infect. 2023;29(5):570–7.
pubmed: 36642173
pmcid: 9837206
doi: 10.1016/j.cmi.2023.01.007
Fugazzaro S, Contri A, Esseroukh O, Kaleci S, Croci S, Massari M et al. Rehabilitation interventions for Post-acute COVID-19 syndrome: a systematic review. Int J Environ Res Public Health. 2022;19(9).
Sakai T, Hoshino C, Hirao M, Nakano M, Takashina Y, Okawa A. Rehabilitation of patients with Post-COVID-19 syndrome: a narrative review. Prog Rehabil Med. 2023;8:20230017.
pubmed: 37323367
pmcid: 10261367
doi: 10.2490/prm.20230017
Anaya JM, Rojas M, Salinas ML, Rodríguez Y, Roa G, Lozano M, et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021;20(11):102947.
pubmed: 34509649
pmcid: 8428988
doi: 10.1016/j.autrev.2021.102947
AWMF online. S3-Leitlinie - Empfehlungen zur Therapie von Patienten mit COVID-19 2023. https://register.awmf.org/assets/guidelines/113-001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19_2023-03.pdf . Accessed 21. March 2024.
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen 2024. https://www.bfarm.de/SharedDocs/Downloads/DE/Kodiersysteme/ATC/atc-ddd-amtlich-2024.pdf?__blob=publicationFile . Accessed 21. March 2024.
Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Board on the Health of Select Populations, Institute of Medicine. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. Washington (DC): National Academies Press (US); 2015. The National Academies Collection: Reports funded by National Institutes of Health.
Bygdell M, Leach S, Lundberg L, Gyll D, Martikainen J, Santosa A, et al. A comprehensive characterization of patients diagnosed with post-COVID-19 condition in Sweden 16 months after the introduction of the International classification of diseases Tenth Revision diagnosis code (U09.9): a population-based cohort study. Int J Infect Dis. 2023;126:104–13.
pubmed: 36410693
doi: 10.1016/j.ijid.2022.11.021
FAIR Health I. Patients diagnosed with post-COVID conditions: an analysis of private healthcare claims using the official ICD-10 diagnostic code FAIR Health white paper 2022.
Adorjan K. Post-COVIDLMU: implementation and evaluation of an interdisciplinary and cross-sectoral healthcare and research network for evidence-based treatment of patients with severe post-COVID syndrome. Nervenarzt. 2022;93(8):797–803.
pubmed: 35695907
pmcid: 9190193
doi: 10.1007/s00115-022-01322-1
Wang L, Foer D, Zhang Y, Karlson EW, Bates DW, Zhou L, Post-Acute. COVID-19 respiratory symptoms in patients with asthma: an Electronic Health records-based study. J Allergy Clin Immunol Pract. 2023;11(3):825–e353.
pubmed: 36566779
doi: 10.1016/j.jaip.2022.12.003
Premraj L, Kannapadi NV, Briggs J, Seal SM, Battaglini D, Fanning J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci. 2022;434:120162.
pubmed: 35121209
pmcid: 8798975
doi: 10.1016/j.jns.2022.120162
Low PA, Opfer-Gehrking TL, Textor SC, Benarroch EE, Shen WK, Schondorf R, et al. Postural tachycardia syndrome (POTS). Neurology. 1995;45(4 Suppl 5):S19–25.
pubmed: 7746369
Ormiston CK, Świątkiewicz I, Taub PR. Postural orthostatic tachycardia syndrome as a sequela of COVID-19. Heart Rhythm. 2022;19(11):1880–9.
pubmed: 35853576
pmcid: 9287587
doi: 10.1016/j.hrthm.2022.07.014
Busch MA, Maske UE, Ryl L, Schlack R, Hapke U. [Prevalence of depressive symptoms and diagnosed depression among adults in Germany: results of the German health interview and examination survey for adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5–6):733–9.
pubmed: 23703492
doi: 10.1007/s00103-013-1688-3
Steppuhn H, Kuhnert R, Scheidt-Nave C. 12-month prevalence of asthma among adults in Germany. J Health Monit. 2017;2(3):34–42.
pubmed: 37168951
pmcid: 10165913
Sunata K, Miyata J, Terai H, Matsuyama E, Watase M, Namkoong H et al. Asthma is a risk factor for general fatigue of long COVID in Japanese nation-wide cohort study. Allergol Int. 2023.
Mazza MG, Palladini M, Villa G, De Lorenzo R, Rovere Querini P, Benedetti F. Prevalence, trajectory over time, and risk factor of post-COVID-19 fatigue. J Psychiatr Res. 2022;155:112–9.
pubmed: 36029623
pmcid: 9391361
doi: 10.1016/j.jpsychires.2022.08.008
Wang S, Quan L, Chavarro JE, Slopen N, Kubzansky LD, Koenen KC, et al. Associations of depression, anxiety, worry, perceived stress, and loneliness prior to infection with risk of post-COVID-19 conditions. JAMA Psychiatry. 2022;79(11):1081–91.
pubmed: 36069885
pmcid: 9453634
doi: 10.1001/jamapsychiatry.2022.2640
Koczulla A. S1-Leitlinie Long/ Post-COVID: AWMF online; 2023. https://register.awmf.org/assets/guidelines/020-027l_S1_Long-Post-Covid_2023-11.pdf . Accessed 21. March 2024.
Schettler V. Apheresetherapie bei Patientinnen und Patienten mit Long-/Post-COVID-Syndrom (aktualisiert): Deutsche Gesellschaft für Nephrologie; 2022. https://www.dgfn.eu/stellungnahmen-details/apheresetherapie-long-post-covid-syndrom.html . Accessed 21. March 2024.
Al-Jabr H, Hawke LD, Thompson DR, Clifton A, Shenton M, Castle DJ, Ski CF. Interventions to support mental health in people with long COVID: a scoping review. BMC Public Health. 2023;23(1):1186.
pubmed: 37340400
pmcid: 10280822
doi: 10.1186/s12889-023-16079-8
Grande T, Grande B, Gerner P, Hammer S, Stingl M, Vink M, Hughes BM. The role of pychotherapy in the care of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Med (Kaunas). 2023;59(4).
Kupferschmitt A, Jöbges M, Randerath J, Hinterberger T, Loew TH, Köllner V. Attention deficits and depressive symptoms improve differentially after rehabilitation of post-COVID condition - A prospective cohort study. J Psychosom Res. 2023;175:111540.
pubmed: 37918327
doi: 10.1016/j.jpsychores.2023.111540
El-Tallawy SN, Perglozzi JV, Ahmed RS, Kaki AM, Nagiub MS, LeQuang JK, Hadarah MM. Pain Management in the Post-COVID Era-An update: a narrative review. Pain Ther. 2023;12(2):423–48.
pubmed: 36853484
pmcid: 9971680
doi: 10.1007/s40122-023-00486-1
Reese JT, Blau H, Casiraghi E, Bergquist T, Loomba JJ, Callahan TJ, et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine. 2023;87:104413.
pubmed: 36563487
doi: 10.1016/j.ebiom.2022.104413
Yong SJ, Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol. 2022;32(4):e2315.
pubmed: 34888989
doi: 10.1002/rmv.2315